Heska Corp (HSKA) Posts Earnings Results, Beats Expectations By $0.03 EPS
Heska Corp (NASDAQ:HSKA) announced its earnings results on Thursday. The medical research company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03, Briefing.com reports. Heska Corp had a net margin of 9.81% and a return on equity of 12.52%. The business had revenue of $31.40 million during the quarter, compared to analysts’ expectations of $36.10 million. During the same period in the prior year, the company earned $0.45 earnings per share. The business’s revenue was down 6.0% compared to the same quarter last year.
Heska Corp (HSKA) traded down $10.29 during midday trading on Friday, reaching $86.74. 145,426 shares of the company traded hands, compared to its average volume of 67,052. The stock has a market capitalization of $590.80 million, a PE ratio of 42.81, a PEG ratio of 2.39 and a beta of 0.83. The company has a quick ratio of 1.12, a current ratio of 2.30 and a debt-to-equity ratio of 0.10.
A number of brokerages have recently commented on HSKA. Aegis upped their target price on shares of Heska Corp from $114.50 to $129.50 and gave the company a “buy” rating in a report on Tuesday, August 1st. B. Riley reaffirmed a “neutral” rating and issued a $85.00 target price on shares of Heska Corp in a report on Friday, July 28th. Benchmark Co. reaffirmed a “buy” rating and issued a $120.00 target price (up from $106.00) on shares of Heska Corp in a report on Wednesday, August 9th. BidaskClub raised shares of Heska Corp from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research raised shares of Heska Corp from a “hold” rating to a “buy” rating and set a $109.00 price target for the company in a report on Friday, August 4th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $106.25.
In related news, CFO John Mcmahon sold 2,608 shares of the stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $101.17, for a total transaction of $263,851.36. Following the completion of the transaction, the chief financial officer now directly owns 193 shares of the company’s stock, valued at $19,525.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nancy Wisnewski sold 825 shares of the stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $102.21, for a total transaction of $84,323.25. Following the transaction, the executive vice president now directly owns 38,114 shares of the company’s stock, valued at $3,895,631.94. The disclosure for this sale can be found here. Corporate insiders own 14.70% of the company’s stock.
About Heska Corp
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.